Kazia Therapeutics Sells Cantrixil Rights for $1 Million
Kazia Therapeutics Limited (NASDAQ: KZIA) has announced an agreement that involves selling the intellectual property and trademark rights to its oncology drug candidate, Cantrixil, for $1 million to Vivesto. This crucial move not only reinforces Kazia's financial position but also marks a pivotal point in its ongoing efforts to advance cancer treatment.
Overview of the Transaction
The sale comes as part of a strategic decision following Vivesto’s earlier licensing of global development and commercialization rights for Cantrixil back in March 2021. Although Vivesto had opted against advancing Cantrixil in ovarian cancer, they are now exploring the drug’s preclinical potential for treating hematological malignancies.
Cantrixil is an innovative therapeutic candidate characterized as a benzopyran SMETI inhibitor, classified as TRXE-002-01, that is encapsulated within ?-cyclodextrin. This unique formulation aims to enhance the effectiveness of the active molecule against various cancer types.
CEO's Insights on the Deal
John Friend, M.D., the Chief Executive Officer of Kazia Therapeutics, expressed optimism regarding the agreement with Vivesto. He emphasized that the $1 million received will provide non-dilutive funding essential for propelling Kazia’s proprietary, clinical-stage pipeline forward. This financial boost is expected to significantly enhance their research and development efforts.
Kazia’s Pipeline of Innovative Treatments
Kazia Therapeutics has been on a journey to develop groundbreaking treatments for cancer. Among their lead programs is paxalisib, an investigational drug targeting the PI3K/Akt/mTOR signaling pathway integral to numerous cancers. Paxalisib has demonstrated potential through various clinical trials, including a completed Phase 2/3 trial in glioblastoma, results of which were reported recently. The company is keen on designing further studies aiming for a standard registration approval.
Continued Developments in Cancer Therapeutics
The company is also pursuing other clinical trials involving paxalisib for advanced breast cancer, brain metastases, and primary CNS lymphoma. Encouraging data has emerged from those trials, showcasing the drug's capabilities. Furthermore, since obtaining Orphan Drug Designation and Fast Track Designation for glioblastoma from the FDA, Kazia has made significant strides in oncology.
Research into EVT801
Moreover, Kazia is advancing its research on EVT801, a small molecule designed to inhibit VEGFR3, which holds promise across various tumor types. With positive preclinical data demonstrating efficacy and synergy with existing immuno-oncology agents, EVT801 is positioned for intriguing future developments, and a Phase I study has already been successfully completed.
Conclusion and Future Outlook
The strategic sale of Cantrixil's rights is a noteworthy maneuver for Kazia Therapeutics. By enhancing their financial resources and concentrating on leading investigational drugs like paxalisib and EVT801, Kazia is poised to take significant steps forward in oncology. The oncology landscape continues to evolve, and Kazia remains committed to delivering innovative therapies that could change the lives of cancer patients.
Frequently Asked Questions
What was announced by Kazia Therapeutics?
Kazia Therapeutics announced the sale of Cantrixil's intellectual property and trademarks to Vivesto for $1 million.
What is Cantrixil?
Cantrixil is an oncology drug candidate consisting of a third-generation SMETI inhibitor encapsulated in a cyclodextrin.
How does this sale impact Kazia’s future?
The sale enhances Kazia's financial resources, enabling further development of their clinical-stage pipeline, particularly for paxalisib and EVT801.
What are the potential applications for paxalisib?
Paxalisib is being explored as a treatment for multiple forms of brain cancer and has shown promise in various clinical trials.
What is EVT801?
EVT801 is a small molecule inhibitor targeting VEGFR3, showing encouraging results in preclinical studies and synergy with immuno-oncology therapies.
